Edition:
United States

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

62.16EUR
5:48am EDT
Change (% chg)

€-0.46 (-0.73%)
Prev Close
€62.62
Open
€62.50
Day's High
€62.64
Day's Low
€62.04
Volume
8,561
Avg. Vol
45,576
52-wk High
€69.03
52-wk Low
€50.10

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech proposes to increase dividend by 26 pct
Tuesday, 21 Feb 2017 09:29am EST 

Sartorius Stedim Biotech SA :Proposal to annual general shareholders` meeting to increase dividend by 26.0 pct to 0.42 euro ($0.4425) per share.  Full Article

Sartorius Stedim Biotech H1 revenue up 20.6 pct to 508.8 million euros
Monday, 25 Jul 2016 12:59am EDT 

Sartorius Stedim Biotech SA : H1 revenue 508.8 million euros ($558.41 million) versus 422.0 million euros year ago . H1 net profit 83.5 million euros versus 62.9 million euros year ago . H1 EBITDA 136.4 million euros versus 106.5 million euros year ago . Outlook for 2016 raised . Sales revenues are now expected to increase by about 17 pct to 20 pct in constant currencies .Underlying EBITDA margin is projected to rise about 1.5 percentage points in constant currencies.  Full Article

Sartorius Stedim Biotech Acquires U.S. start up Ksep systems
Wednesday, 6 Jul 2016 03:00am EDT 

Sartorius Stedim Biotech : Acquires U.S. start up Ksep systems . Transaction values Ksep at around $28 million and will be closed by end of July 2016 .Ksep holdings, inc. Expected to achieve significant double-digit growth and to generate around $7 million sales revenues and a strong double-digit EBITDA margin in 2016.  Full Article

Sartorius Stedim Biotech proposes FY 2015 dividend
Wednesday, 24 Feb 2016 07:00pm EST 

Sartorius Stedim Biotech SA:To submit proposal to pay a dividend of 2.00 euros per share for FY 2015, up from 1.30 euros a year earlier.  Full Article

Sartorius Stedim Biotech gives guidance for 2016 and 2020
Monday, 1 Feb 2016 01:00am EST 

Sartorius Stedim Biotech SA:Forecasts 2016 sales revenue will increase 12 pct to 16 pct and underlying EBITDA margin will rise approx. one percentage point​.‍Management anticipates that in 2020 sales revenue will reach about 1.5 to 1.6 billion euros and underlying EBITDA margin will attain about 29 to 30 pct.  Full Article

Sartorius Stedim Biotech raises FY 2015 guidance
Tuesday, 20 Oct 2015 12:59am EDT 

Sartorius Stedim Biotech SA:Outlook for 2015 raised.2015 underlying EBITDA margin in constant currencies is forecasted to reach around 25.5 percent to 26.0 percent (previous guidance: about 25.0 percent to 25.5 percent).2015 sales revenue in constant currencies is now expected to increase about 20 percent (previous guidance: about 15 percent).  Full Article

Sartorius Stedim Biotech and GE Healthcare sign worldwide OEM supply agreement
Monday, 31 Aug 2015 08:00pm EDT 

Sartorius Stedim Biotech SA:Sartorius Stedim Biotech and GE Healthcare sign worldwide OEM supply agreement.Entered into a worldwide OEM supply agreement with GE Healthcare for Sartorius Stedim Biotech's membrane adsorber purification technology, Sartobind.Will manufacture membrane adsorber technologies for GE which will be marketed as part of GE's ReadyToProcess product offerings.  Full Article

Sartorius Stedim Biotech SA upgrade FY 2015 guidance in line with estimates
Tuesday, 21 Jul 2015 01:00am EDT 

Sartorius Stedim Biotech SA:Upgrades its forecast for full year of 2015.2015 underlying EBITDA margin in constant currencies is now forecasted to reach about 25.0 pct to 25.5 pct.FY 2015 EBITDA margin: 25.6 percent - Thomson Reuters I/B/E/S.Sales revenue in constant currencies is now expected to increase about 15 percent for 2015.FY 2015 revenue growth: 17.1 percent - Thomson Reuters I/B/E/S.  Full Article

Sartorius Stedim Biotech SA acquires Cellca
Thursday, 2 Jul 2015 02:20am EDT 

Sartorius Stedim Biotech SA:Acquired Cellca GmbH based in Laupheim, Germany.Founded in 2005, the company with around 30 employees.  Full Article

Sartorius Stedim Biotech raises FY 2015 outlook
Monday, 20 Apr 2015 12:55am EDT 

Sartorius Stedim Biotech SA:Revises its forecast upwards for FY 2015.FY 2015 sales revenue in constant currencies is expected to increase about 7 pct to 10 pct (previous guidance about 4 pct to 7 pct).  Full Article

More From Around the Web

BRIEF-Sartorius Stedim Biotech proposes to increase dividend by 26 pct

* Proposal to annual general shareholders` meeting to increase dividend by 26.0 pct to 0.42 euro ($0.4425) per share Source text for Eikon: Further company coverage: ($1 = 0.9492 euros) (Gdynia Newsroom)